212 related articles for article (PubMed ID: 35137361)
1. The Effects of AT-533 and AT-533 gel on Liver Cytochrome P450 Enzymes in Rats.
Wu Y; Li M; Guo Y; Liu T; Zhong L; Huang C; Ye C; Liu Q; Ren Z; Wang Y
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):345-352. PubMed ID: 35137361
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of cytochrome P450 isoenzyme activity in sheep liver and placental microsomes.
Meakin AS; Amirmostofian M; Darby JR; Holman SL; Morrison JL; Wiese MD
Placenta; 2023 Jan; 131():82-89. PubMed ID: 36527743
[TBL] [Abstract][Full Text] [Related]
4. Interaction between Changan Granule and its main components in the plasma and CYP450 enzymes.
Liu X; Wang Q; Chen M; Tao J; Wang J; Liu S; Hou J; Li D; Wang R
J Ethnopharmacol; 2023 May; 308():116303. PubMed ID: 36841379
[TBL] [Abstract][Full Text] [Related]
5. Spectroscopic observations of β-eudesmol binding to human cytochrome P450 isoforms 3A4 and 1A2, but not to isoforms 2C9, 2C19, and 2D6.
Krenc D; Na-Bangchang K
Xenobiotica; 2022 Feb; 52(2):199-208. PubMed ID: 35139770
[TBL] [Abstract][Full Text] [Related]
6. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 inhibition activities of non-standardized botanical products.
Abduraman MA; Mustafa NH; Yaacob NS; Amanah A; Tan ML
J Ethnopharmacol; 2022 Oct; 296():115406. PubMed ID: 35659627
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome p450 activities.
Rastogi H; Jana S
Phytother Res; 2014 Dec; 28(12):1873-8. PubMed ID: 25196644
[TBL] [Abstract][Full Text] [Related]
10. An improved LC-MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity.
Sreevatsav Adiraju SK; Shekar K; Fraser JF; Smith MT; Ghassabian S
Bioanalysis; 2018 Oct; 10(19):1577-1590. PubMed ID: 30226084
[TBL] [Abstract][Full Text] [Related]
11. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
13. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
14. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.
Youdim KA; Lyons R; Payne L; Jones BC; Saunders K
J Pharm Biomed Anal; 2008 Sep; 48(1):92-9. PubMed ID: 18584988
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity.
De Bock L; Boussery K; Colin P; De Smet J; T'jollyn H; Van Bocxlaer J
Talanta; 2012 Jan; 89():209-16. PubMed ID: 22284482
[TBL] [Abstract][Full Text] [Related]
16. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
Eng H; Obach RS
Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of a New Antiaggregant, Indolinone Derivative.
Bykov VV; Leonov KA; Serebrov VY; Chernysheva GA; Smol'yakova VI; Solov'ev MA; Udut EV; Fisenko VP; Udut VV
Bull Exp Biol Med; 2020 Apr; 168(6):739-742. PubMed ID: 32333310
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents.
Ramasamy S; Kiew LV; Chung LY
Molecules; 2014 Feb; 19(2):2588-601. PubMed ID: 24566323
[TBL] [Abstract][Full Text] [Related]
19. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
